Addition of aliskiren to olmesartan ameliorates tubular injury in chronic kidney disease patients partly by reducing proteinuria

JRAAS - Journal of the Renin-Angiotensin-Aldosterone System

Volumn 13, Issue 1, 2012, Pages 122-127

  Nakamura, Tsukasa ^a   Sato, Eiichi ^a   Amaha, Mayuko ^a   Kawagoe, Yasuhiro ^a   Maeda, Sayaka ^b   Yamagishi, Sho Ichi ^b  

^a Shinmatsudo Central General Hospital   (Japan)

^b KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Aliskiren; CKD; L FABP; proteinuria; RAS

Indexed keywords

ALISKIREN; CREATININE; FATTY ACID BINDING PROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OLMESARTAN; TRIACYLGLYCEROL;

ARTICLE; BODY MASS; CHRONIC KIDNEY DISEASE; CLINICAL ARTICLE; CREATININE BLOOD LEVEL; DIASTOLIC BLOOD PRESSURE; DRUG EFFECT; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY TUBULE DAMAGE; MALE; MONOTHERAPY; PROTEIN URINE LEVEL; PROTEINURIA; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL; UREA NITROGEN BLOOD LEVEL;

ADULT; AMIDES; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; DRUG THERAPY, COMBINATION; FATTY ACID-BINDING PROTEINS; FEMALE; FUMARATES; HUMANS; IMIDAZOLES; KIDNEY FAILURE, CHRONIC; KIDNEY TUBULES; MALE; PROTEINURIA; REGRESSION ANALYSIS; TETRAZOLES;

EID: 84859995267     PISSN: 14703203     EISSN: 17528976     Source Type: Journal    
DOI: 10.1177/1470320311422580     Document Type: Article

References (27)

1. Yamagishi S, Fukami K, Ueda S and Okuda S. Molecular mechanisms of diabetic nephropathy and its therapeutic intervention. Curr Drug Targets 2007; 8: 952-959.
2. Ziyadeh FN and Goldfarb S. The renal tubulointerstitium in diabetes mellitus. Kidney Int 1991; 39: 464-475.
3. Taft JL, Nolan CJ, Yeung SP, Hewitson TD and Martin FI. Clinical and histological correlations of decline in renal function in diabetic patients with proteinuria. Diabetes 1994; 43: 1046-1051. (Pubitemid 24230711)
4. Burton C and Harris KP. The role of proteinuria in the progression of chronic renal failure. Am J Kidney Dis 1996; 27: 765-775. (Pubitemid 26169027)
5. D'Amico G and Bazzi C. Pathophysiology of proteinuria. Kidney Int 2003; 63: 809-825. (Pubitemid 36315559)
6. Lewis EJ, Hunsicker LG, Bain RP and Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 1993; 329: 1456-1462. (Pubitemid 23335891)
7. Ravid M, Savin H, Jutrin I, Bental T, Katz B and Lishner M.Long-term stabilizing effect of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type II diabetic patients. Ann Intern Med 1993; 118: 577-581. (Pubitemid 23102690)
8. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, et al. Collaborative Study Group. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345: 851-860.
9. Haller H, Ito S, Izzo JL Jr, Januszewicz A, Katayama S, Menne J,et al. Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes. N Engl J Med 2011; 364: 907-917.
10. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861-889.
11. Cao Z and Cooper ME. Role of angiotensin II in tubulointerstitial injury. Semin Nephrol 2001; 21: 554-562. (Pubitemid 33091937)
12. Kelly DJ, Cox AJ, Tolcos M, Cooper ME, Wilkinson-Berka JL and Gilbert RE. Attenuation of tubular apoptosis by blockade of the renin-angiotensin system in diabetic Ren-2 rats. Kidney Int 2002; 61: 31-39. (Pubitemid 34075128)
13. Matsui T, Yamagishi S, Takeuchi M, Ueda S, Fukami K and Okuda S. Irbesartan inhibits advanced glycation end product (AGE)-induced proximal tubular cell injury in vitro by suppressing receptor for AGEs (RAGE) expression. Pharmacol Res 2010; 61: 34-39.
14. Yamagishi S, Nakamura K and Matsui T. Potential utility of telmisartan, an angiotensin II type 1 receptor blocker with peroxisome proliferator-activated receptor-gamma (PPAR-gamma)-modulating activity for the treatment of cardiometabolic disorders. Curr Mol Med 2007; 7: 463-469. (Pubitemid 47244891)
15. Ichihara A, Kaneshiro Y, Takemitsu T, Sakoda M and Itoh H. The (pro)renin receptor and the kidney. Semin Nephrol 2007; 27: 524-528. (Pubitemid 47374903)
16. Balakumar P and Jagadeesh G. Cardiovascular and renal pathologic implications of prorenin, renin, and the (pro)renin receptor: promising young players from the old renin-angiotensin-aldosterone system. J Cardiovasc Pharmacol 2010; 56: 570-579.
17. Nguyen G. Renin, (pro)renin and receptor: an update. Clin Sci (Lond) 2011; 120: 169-178.
18. Riccioni G. Aliskiren in the treatment of hypertension and organ damage. Cardiovasc Ther 2011; 29: 77-87.
19. Parving HH, Persson F, Lewis JB, Lewis EJ, Hollenberg NK; AVOID Study Investigators. Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med 2008; 358: 2433-2446. (Pubitemid 351793017)
20. Kamijo A, Sugaya T, Hikawa A, Yamanouchi M, Hirata Y, Ishimitsu T, et al. Clinical evaluation of urinary excretion of liver-type fatty acid-binding protein as a marker for the monitoring of chronic kidney disease. A multicenter trial. J Lab Clin Med 2005; 145: 125-133. (Pubitemid 40432361)
21. Imai E, Horio M, Nitta K, Yamagata K, Iseki K, Hara S, et al.Estimation of glomerular filtration rate by MDRD study equation modified for Japanese patients with chronic kidney disease. Clin Exp Nephrol 2007; 11: 41-50. (Pubitemid 46474965)
22. Matsui T, Yamagishi S, Ueda S, Fukami K and Okuda S. Irbesartan inhibits albumin-elicited proximal tubular cell apoptosis and injury in vitro. Protein Pept Lett 2010; 17: 74-77.
23. Hayashi M, Tomobe K, Hirabayashi H, Hoshimoto K, Ohkura T and Inaba N. Increased excretion of N-acetyl-beta-D-glucosaminidase and beta2-microglobulin in gestational week 30. Am J Med Sci 2001; 321: 168-172. (Pubitemid 32209918)
24. Yokoyama T, Kamijo-Ikemori A, Sugaya T, Hoshino S, Yasuda T and Kimura K. Urinary excretion of liver type fatty acid binding protein accurately reflects the degree of tubulointerstitial damage. Am J Pathol 2009; 174: 2096-2106.
25. Go AS, Chertow GM, Fan D, McCulloch CE and Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004; 351: 1296-1305.
26. Nakamura T, Sato E, Fujiwara N, Kawagoe Y, Ueda Y, Suzuki T, et al. Co-administration of ezetimibe enhances proteinuria-lowering effects of pitavastatin in chronic kidney disease patients partly via a cholesterol-independent manner. Pharmacol Res 2010; 61: 58-61.
27. Nakamura T, Sato E, Fujiwara N, Kawagoe Y, Ueda Y, Suzuki T,et al. Ezetimibe decreases serum levels of asymmetric dimethylarginine (ADMA) and ameliorates renal injury in non-diabetic chronic kidney disease patients in a cholesterol-independent manner. Pharmacol Res 2009; 60: 525-528.